Aeterna Zentaris Inc (AEZS.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2016||Independent Chairman of the Board|
|2017||President, Chief Executive Officer, Director|
|58||2017||Interim Chief Financial Officer|
|2014||Senior Vice President, Chief Scientific Officer, Chief Medical Officer|
|2013||Chief Commercial Officer, Senior Vice President|
- BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris
- BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada
- BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore
- BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
- Canada's Aeterna gets FDA approval for growth hormone deficiency test